PTC Therapeutics, Inc.
PTCT
$66.71
$2.223.44%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -21.96% | 17.96% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -21.96% | 17.96% | |||
| Cost of Revenue | 20.82% | -6.81% | |||
| Gross Profit | -74.12% | 74.55% | |||
| SG&A Expenses | 15.26% | -1.43% | |||
| Depreciation & Amortization | 24.09% | 85.52% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 18.69% | -2.91% | |||
| Operating Income | -2,440.14% | 110.01% | |||
| Income Before Tax | -502.77% | 67.53% | |||
| Income Tax Expenses | 89.43% | -528.24% | |||
| Earnings from Continuing Operations | -949.05% | 124.51% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -949.05% | 124.51% | |||
| EBIT | -2,440.14% | 110.01% | |||
| EBITDA | -570.80% | 153.52% | |||
| EPS Basic | -925.57% | 124.42% | |||
| Normalized Basic EPS | -365.05% | 55.92% | |||
| EPS Diluted | -957.30% | 123.51% | |||
| Normalized Diluted EPS | -416.25% | 60.29% | |||
| Average Basic Shares Outstanding | 2.83% | 0.41% | |||
| Average Diluted Shares Outstanding | -7.38% | 11.47% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||